Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.

Britt RoosenboomPeter J WahabCarolijn SmidsJos MeijerLarissa G J M KempermanMarcel J M GroenenEllen G van LochemCarmen S Horjus Talabur Horje

Published in: Inflammatory bowel diseases (2023)

UC responders to vedolizumab have a higher percentage of α4β7+CD3+ T lymphocytes and a higher proportion of MAdCAM-1+ venules in colonic biopsies than nonresponders before initiating therapy. Both analyses could be promising predictive biomarkers for therapeutic response and may lead to more patient tailored treatment in the future.

Keyphrases

ulcerative colitis
case report
peripheral blood
current status
combination therapy
nk cells
cell therapy